Slovakia – Pharmaceutical products – MEDICINES FOR BIOLOGICAL TREATMENT 2026

Opportunity description

The subject of the contract is the supply of medicines for biological treatment. A detailed definition of the subject of the contract is provided in Part B.1 “Description of the subject of the contract” and Part B.2 “Commercial terms for delivery of the subject of the contract” of the tender documents. The subject of this part of the contract is the supply of a medicine with the active substance Belimumab in accordance with the specification provided in Part B.1 “Description of the subject of the contract” and Part B.2 “Commercial terms for delivery of the subject of the contract” of the tender documents. The subject of this part of the contract is the supply of a medicine with the active substance Abatacept in accordance with the specification provided in Part B.1 “Description of the subject of the contract” and Part B.2 “Commercial terms for delivery of the subject of the contract” of the tender documents. The subject of this part of the contract is the supply of a medicine with the active substance Infliximab in accordance with the specification provided in Part B.1 “Description of the subject of the contract” and Part B.2 “Commercial terms for delivery of the subject of the contract” of the tender documents. The subject of this part of the contract is the supply of a medicine with the active substance Tocilizumab in accordance with the specification provided in Part B.1 “Description of the subject of the contract” and Part B.2 “Commercial terms for delivery of the subject of the contract” of the tender documents. The subject of this part of the contract is the supply of a medicine with the active substance Anifrolumab in accordance with the specification provided in Part B.1 “Description of the subject of the contract” and Part B.2 “Commercial terms for delivery of the subject of the contract” of the tender documents. The subject of this part of the contract is the supply of a medicine with the active substance Rituximab in accordance with the specification provided in Part B.1 “Description of the subject of the contract” and Part B.2 “Commercial terms for delivery of the subject of the contract” of the tender documents. Procedure: open. Review the original TED notice for the complete requirement, lots, amendments and attachments.